Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C

Aim From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety of this combination t...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2017-12, Vol.47 (13), p.1429-1437
Main Authors: Atsukawa, Masanori, Tsubota, Akihito, Koushima, Yohei, Ikegami, Tadashi, Watanabe, Kouji, Shimada, Noritomo, Sato, Shinichi, Kato, Keizo, Abe, Hiroshi, Okubo, Tomomi, Arai, Taeang, Itokawa, Norio, Kondo, Chisa, Mikami, Shigeru, Asano, Toru, Chuganji, Yoshimichi, Matsuzaki, Yasushi, Iwakiri, Katsuhiko
Format: Article
Language:English
Subjects:
chronic hepatitis C
Dialysis
Disease resistance
End-stage renal disease
Erythema
Erythema multiforme
Genotype & phenotype
genotype 1b
Glomerular filtration rate
Hemodialysis
Hepatitis
Hepatitis C
Interferon
Kidney diseases
Kidney transplantation
Liver
ombitasvir/paritaprevir/ritonavir
Pruritus
Renal function
Ritonavir
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this study was to assess the efficacy and safety of this combination that have not yet been addressed in patients undergoing dialysis. Methods A retrospective, multicenter study evaluated the outcome of 12‐week ombitasvir (non‐structural protein [NS]5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir combination therapy for dialysis patients. The primary end‐point was sustained virologic response 12 weeks after therapy (SVR12). Results The subjects were 31 patients with a median age of 64 years (range, 49–85 years), including 10 cirrhotic patients. All of the 31 patients had an estimated glomerular filtration rate level 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.12910